


CLAIMS


We claim:

- 5 1. A compound of Formula I



wherein:

- 10 A is hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>aminoalkyl, or a heterocycle selected from the group consisting



W is NR<sup>3</sup>, O, or S;

- 15 R<sup>1</sup> is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxy carbonyl;

R<sup>2</sup> is C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl;

20

R<sup>3</sup> is hydrogen or C<sub>1-6</sub>alkyl;

m is 0, 1, 2, or 3;

25

n is 1 or 2;

X is CO or SO<sub>2</sub>;


- 30 B is selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylmethyl; C<sub>1-3</sub>methoxyalkyl, and C<sub>1-3</sub>phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl,

benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and  $-N(R^3)_2$ ;

or a pharmaceutically acceptable salt or solvate.


5

2. A compound of claim 1 where the carbon marked with an asterisk is of the (R) stereochemistry.



10

3. A compound of claim 1 where A is  $C_{1-4}$ aminoalkyl, or a heterocycle selected from



4. A compound of claim 1 where m is 1 and  $R^1$  is phenyl substituted with 1-2 substituents selected from halo, alkyl, alkyloxy, cyano, carboalkoxy.

15

5. A compound of claim 1 where X is CO and B is selected from  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkylmethyl,  $C_{1-3}$ methoxyalkyl, and  $C_{1-3}$ phenoxyalkyl or is selected from phenyl, pyrazinyl, furanyl, isoxazolyl, and benzthienyl, moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and  $-N(R^3)_2$ .

20

6. A compound of claim 1 where n is 1.

7. The compound of claim 7: N-[1-[(2R)-3-(4-Chlorophenyl)-2-[[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-azetidiny]-N-cyclohexyl-3-methyl-butanamide.


25

8. A compound of claim 1 where n is 2.

9. A compound of claim 8 where the carbon marked with an asterisk is of the (S) stereochemistry.

30

35



10. A compound of claim 9 selected from the following group:

- 5 (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- 10 (2S)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(1-oxopentyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(2-furanylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- 15 N-[1-[(2R)-3-(4-Chlorophenyl)-2-[(3S)-[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-pyrrolidinyl]-N-cyclohexyl-3-methyl-butanamide; and
- 20 (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(methylsulfonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide.

11. A pharmaceutical composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

25

12. A method for treating a patient afflicted with a condition responsive to the modulation of melanocortin receptors comprising administration of a therapeutically effective amount of a compound of claim 1.